Rationale for the continued use of melatonin to combat the delta variant of SARS-CoV-2

Autores
Reiter, Russel J.; Cardinali, Daniel Pedro; Neel, Richard L.; Domínguez Rodriguez, Alberto; Brown, Gregory M.; Tesarik, Jan
Año de publicación
2021
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Fil: Reiter, Russel J. University of Texas Health Science Center at San Antonio. Department of Cell Systems and Anatomy; Estados Unidos
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Medicas; Argentina
Fil: Neel, Richard L. Family Doctor; Estados Unidos
Fil: Dominguez Rodriguez, Alberto. University Hospital of Canary Islands San Cristóbal de La Laguna. Department of Cardiology; España
Fil: Brown, Gregory M. University of Toronto. Department of Psychiatry; Canada
Fil: Tesarik, Jan. MAR & Gen Clinic Granada; España
Abstract: Melatonin was shown to prevent or mitigate a number of different respiratory and nonrespiratory viral diseases. Given its non-specific anti-viral action, it is likely to be effective against the delta variant of SARS-CoV-2 as well as any eventual future variants of the virus.
Fuente
Melatonin Research Vol. 4, No.3, 2021
Materia
MELATONINA
SARS-CoV-19
VARIANTE DELTA COVID-19
VARIANTES FUTURAS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
Repositorio Institucional (UCA)
Institución
Pontificia Universidad Católica Argentina
OAI Identificador
oai:ucacris:123456789/13671
Acceder
id RIUCA_81c303aa9790928714270c336623b45e
oai_identifier_str oai:ucacris:123456789/13671
network_acronym_str RIUCA
repository_id_str 2585
network_name_str Repositorio Institucional (UCA)
spelling Rationale for the continued use of melatonin to combat the delta variant of SARS-CoV-2Reiter, Russel J.Cardinali, Daniel PedroNeel, Richard L.Domínguez Rodriguez, AlbertoBrown, Gregory M.Tesarik, JanMELATONINASARS-CoV-19VARIANTE DELTA COVID-19VARIANTES FUTURASFil: Reiter, Russel J. University of Texas Health Science Center at San Antonio. Department of Cell Systems and Anatomy; Estados UnidosFil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Medicas; ArgentinaFil: Neel, Richard L. Family Doctor; Estados UnidosFil: Dominguez Rodriguez, Alberto. University Hospital of Canary Islands San Cristóbal de La Laguna. Department of Cardiology; EspañaFil: Brown, Gregory M. University of Toronto. Department of Psychiatry; CanadaFil: Tesarik, Jan. MAR & Gen Clinic Granada; EspañaAbstract: Melatonin was shown to prevent or mitigate a number of different respiratory and nonrespiratory viral diseases. Given its non-specific anti-viral action, it is likely to be effective against the delta variant of SARS-CoV-2 as well as any eventual future variants of the virus.ST-Bio-Life LLC2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://repositorio.uca.edu.ar/handle/123456789/136712641-0281 (online)10.32794/mr112500107Reiter, R.J. et al. Rationale for the continued use of melatonin to combat the delta variant of SARS-CoV-2 [en línea]. Melatonin Research. 2021, 4 (3). doi: 10.32794/mr112500107. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/13671Melatonin Research Vol. 4, No.3, 2021reponame:Repositorio Institucional (UCA)instname:Pontificia Universidad Católica Argentinaenginfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/2025-07-03T10:58:30Zoai:ucacris:123456789/13671instacron:UCAInstitucionalhttps://repositorio.uca.edu.ar/Universidad privadaNo correspondehttps://repositorio.uca.edu.ar/oaiclaudia_fernandez@uca.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:25852025-07-03 10:58:30.38Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentinafalse
dc.title.none.fl_str_mv Rationale for the continued use of melatonin to combat the delta variant of SARS-CoV-2
title Rationale for the continued use of melatonin to combat the delta variant of SARS-CoV-2
spellingShingle Rationale for the continued use of melatonin to combat the delta variant of SARS-CoV-2
Reiter, Russel J.
MELATONINA
SARS-CoV-19
VARIANTE DELTA COVID-19
VARIANTES FUTURAS
title_short Rationale for the continued use of melatonin to combat the delta variant of SARS-CoV-2
title_full Rationale for the continued use of melatonin to combat the delta variant of SARS-CoV-2
title_fullStr Rationale for the continued use of melatonin to combat the delta variant of SARS-CoV-2
title_full_unstemmed Rationale for the continued use of melatonin to combat the delta variant of SARS-CoV-2
title_sort Rationale for the continued use of melatonin to combat the delta variant of SARS-CoV-2
dc.creator.none.fl_str_mv Reiter, Russel J.
Cardinali, Daniel Pedro
Neel, Richard L.
Domínguez Rodriguez, Alberto
Brown, Gregory M.
Tesarik, Jan
author Reiter, Russel J.
author_facet Reiter, Russel J.
Cardinali, Daniel Pedro
Neel, Richard L.
Domínguez Rodriguez, Alberto
Brown, Gregory M.
Tesarik, Jan
author_role author
author2 Cardinali, Daniel Pedro
Neel, Richard L.
Domínguez Rodriguez, Alberto
Brown, Gregory M.
Tesarik, Jan
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv MELATONINA
SARS-CoV-19
VARIANTE DELTA COVID-19
VARIANTES FUTURAS
topic MELATONINA
SARS-CoV-19
VARIANTE DELTA COVID-19
VARIANTES FUTURAS
dc.description.none.fl_txt_mv Fil: Reiter, Russel J. University of Texas Health Science Center at San Antonio. Department of Cell Systems and Anatomy; Estados Unidos
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Medicas; Argentina
Fil: Neel, Richard L. Family Doctor; Estados Unidos
Fil: Dominguez Rodriguez, Alberto. University Hospital of Canary Islands San Cristóbal de La Laguna. Department of Cardiology; España
Fil: Brown, Gregory M. University of Toronto. Department of Psychiatry; Canada
Fil: Tesarik, Jan. MAR & Gen Clinic Granada; España
Abstract: Melatonin was shown to prevent or mitigate a number of different respiratory and nonrespiratory viral diseases. Given its non-specific anti-viral action, it is likely to be effective against the delta variant of SARS-CoV-2 as well as any eventual future variants of the virus.
description Fil: Reiter, Russel J. University of Texas Health Science Center at San Antonio. Department of Cell Systems and Anatomy; Estados Unidos
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://repositorio.uca.edu.ar/handle/123456789/13671
2641-0281 (online)
10.32794/mr112500107
Reiter, R.J. et al. Rationale for the continued use of melatonin to combat the delta variant of SARS-CoV-2 [en línea]. Melatonin Research. 2021, 4 (3). doi: 10.32794/mr112500107. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/13671
url https://repositorio.uca.edu.ar/handle/123456789/13671
identifier_str_mv 2641-0281 (online)
10.32794/mr112500107
Reiter, R.J. et al. Rationale for the continued use of melatonin to combat the delta variant of SARS-CoV-2 [en línea]. Melatonin Research. 2021, 4 (3). doi: 10.32794/mr112500107. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/13671
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv ST-Bio-Life LLC
publisher.none.fl_str_mv ST-Bio-Life LLC
dc.source.none.fl_str_mv Melatonin Research Vol. 4, No.3, 2021
reponame:Repositorio Institucional (UCA)
instname:Pontificia Universidad Católica Argentina
reponame_str Repositorio Institucional (UCA)
collection Repositorio Institucional (UCA)
instname_str Pontificia Universidad Católica Argentina
repository.name.fl_str_mv Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentina
repository.mail.fl_str_mv claudia_fernandez@uca.edu.ar
_version_ 1836638361016598528
score 13.13397

Publicaciones similares